Halozyme Therapeutics, Inc.HALONASDAQ
Loading
EBITDA as a percentage of revenue
3Y CAGR
+13.0%/yr
Annual compound
5Y CAGR
+3.9%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
1.2x
Modest growth
Streak
3 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | 69.05% | +6.8% |
| 2024 | 64.66% | +18.6% |
| 2023 | 54.50% | +14.0% |
| 2022 | 47.80% | -18.2% |
| 2021 | 58.43% | +2.2% |
| 2020 | 57.16% | +298.1% |
| 2019 | -28.86% | +36.8% |
| 2018 | -45.65% | -273.8% |
| 2017 | 26.27% | +148.5% |
| 2016 | -54.18% | - |